Home
In the preclinical research facilities at the Turku PET Centre, molecules labeled with positron-emitting radionuclides are used in various in vivo, ex vivo, and in vitro biological models in order to determine their suitability as PET tracers, or as tools in preclinical research.
Preclinical evaluations of new PET radiotracers are generally carried out as soon as the tracers become available from radiochemistry. By evaluating lead molecules at the earliest possible stage, tracers of less promise can be halted in the early stages of development. Radiotracers are also used to investigate biological phenomena and the progress of different pathological conditions, such as cancer, and neurological- and metabolism-related diseases, or as tools in drug development.